Anthos' blood thinner cuts the risk of bleeding amid race to develop safer anticoagulants
PHILADELPHIA — An anticoagulant from Anthos Therapeutics substantially cut the risk of bleeding compared to Xarelto in a mid-stage safety study.
The Anthos drug is part of an up-and-coming class of investigational anticoagulants that clinicians and companies hope will offer patients a better, safer option for preventing stroke and blood clots over currently available pills.
The risk of bleeding is one of the most feared effects of current blood thinners, which are prescribed for people after they have had certain surgeries or for those with atrial fibrillation — an irregular heartbeat that can lead to stroke.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.